Shilpa Medicare gets WHO-Geneva nod for API, Tenofovir Disoproxil Fumarate for HIV, Hepatitis B

Written by Ruchika Sharma Published On 2021-07-30T12:00:20+05:30 | Updated On 30 July 2021 6:17 PM IST

Shilpa Medicare gets WHO-Geneva nod for API, Tenofovir Disoproxil Fumarate for HIV, Hepatitis B

Karnataka: Shilpa Medicare Limited has recently announced the receipt of confirmation of WHO - GENEVA approval for API, Tenofovir Disoproxil Fumarate.

The medication is used to treat chronic hepatitis B and to prevent and treat HIV / AIDS, under pre-qualification program.

Shilpa Medicare Limited started its operations as API manufacturer way back in 1987 at Raichur, Karnataka- India. The commercial production in the SML was started in November 1989.

Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of affordable API and Formulation globally in different regulated markets.

Read also: Dr Reddys, Shilpa Medicare ink agreement for Sputnik V production

shilpa medicareshilpa medicare newstenofovir disoproxil fumaratehivhepatitis b

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751